Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 4/2018

Open Access 01-12-2018 | Review Article

Faecal Occult Blood Point-of-Care Tests

Authors: Barbara Kościelniak-Merak, Branimir Radosavljević, Andrzej Zając, Przemysław J. Tomasik

Published in: Journal of Gastrointestinal Cancer | Issue 4/2018

Login to get access

Abstract

Background

Early detection of colorectal cancer decreases the risk of mortality. Faecal occult blood tests (FOBT) are recognised as a useful tool for colorectal cancer screening. These non-invasive, rapid, and easy-to-carry assays are very often used as a point-of-care test and for self-testing. On the market, there are various types of FOB tests available, including chemical and immunochromatographic tests, which are based on different detection methods and differ in their sensitivity and specificity.

Conclusions

Clinicians should be aware of the causes of false-negative and false-positive test results, which can vary depending on the test. Additionally, stool sampling bias may be a source of error and must be considered by the clinician. The current FOBT methods are subject to various interfering factors; items such as proper preparation of the patient prior to testing or the clinician’s knowledge of testing limitations are key in correct interpreting results. Novel technologies such as FOBT DNA tests, micro RNA tests, and biochips equipped with bacteria can indicate bleeding from the gastrointestinal tract and improve diagnostics process.
Literature
1.
go back to reference Craven O. Screening for colorectal cancer using the fecal occult blood test: a critical literature review. Eur J Oncol Nurs. 2001;5:234–43.CrossRef Craven O. Screening for colorectal cancer using the fecal occult blood test: a critical literature review. Eur J Oncol Nurs. 2001;5:234–43.CrossRef
2.
go back to reference Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med. 1997;126:811–22.CrossRef Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med. 1997;126:811–22.CrossRef
3.
go back to reference Villeneuve PJ, Coombs A. Screening for colorectal cancer using the fecal occult blood test: an actuarial assessment of the impact of a population-based screening program in Canada. Int J Technol Assess Health Care. 2003;19:715–23.CrossRef Villeneuve PJ, Coombs A. Screening for colorectal cancer using the fecal occult blood test: an actuarial assessment of the impact of a population-based screening program in Canada. Int J Technol Assess Health Care. 2003;19:715–23.CrossRef
4.
go back to reference American Cancer Society. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society; 2018. American Cancer Society. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society; 2018.
6.
go back to reference Health Quality Ontario. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9:1–40.PubMedCentral Health Quality Ontario. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9:1–40.PubMedCentral
7.
go back to reference Santare D, Kojalo I, Huttunen T. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol. 2015;27:536–43.CrossRef Santare D, Kojalo I, Huttunen T. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol. 2015;27:536–43.CrossRef
8.
go back to reference Khakimov N, Khasanova G, Ershova K, Gibadullina L, Vetkina T, Lobisheva G, et al. Screening for colon cancer: a test for occult blood. Int J Risk Saf Med. 2015;27(Suppl 1):S110–1.CrossRef Khakimov N, Khasanova G, Ershova K, Gibadullina L, Vetkina T, Lobisheva G, et al. Screening for colon cancer: a test for occult blood. Int J Risk Saf Med. 2015;27(Suppl 1):S110–1.CrossRef
10.
go back to reference Leontiadis GI. Fecal immunochemical tests in patients at increased risk for colorectal cancer-is it prime time yet? JAMA Intern Med. 2017;177:1119–20.CrossRef Leontiadis GI. Fecal immunochemical tests in patients at increased risk for colorectal cancer-is it prime time yet? JAMA Intern Med. 2017;177:1119–20.CrossRef
11.
go back to reference Benton SC, Seaman HE, Halloran SP. Faecal occult blood testing for colorectal cancer screening: the past or the future. Curr Gastroenterol Rep. 2015;17:428.CrossRef Benton SC, Seaman HE, Halloran SP. Faecal occult blood testing for colorectal cancer screening: the past or the future. Curr Gastroenterol Rep. 2015;17:428.CrossRef
12.
go back to reference Greenwald B. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening. Gastroenterol Nurs. 2005;28:90–6.CrossRef Greenwald B. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening. Gastroenterol Nurs. 2005;28:90–6.CrossRef
13.
go back to reference Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003;115:111–4.CrossRef Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003;115:111–4.CrossRef
14.
go back to reference Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015;64:1327–37.CrossRef Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015;64:1327–37.CrossRef
15.
go back to reference Dybdahl JH, Daae LN, Larsen S. Occult faecal blood loss determined by chemical tests and a 51 Cr method. Scand J Gastroenterol. 1981;16:245–52.CrossRef Dybdahl JH, Daae LN, Larsen S. Occult faecal blood loss determined by chemical tests and a 51 Cr method. Scand J Gastroenterol. 1981;16:245–52.CrossRef
16.
go back to reference Foliente RL, Wise GR, Collen MJ, Abdulian JD, Chen YK. Colocare self-test versus Hemoccult II SENSA for fecal occult blood testing. Am J Gastroenterol. 1995;90:2160–3.PubMed Foliente RL, Wise GR, Collen MJ, Abdulian JD, Chen YK. Colocare self-test versus Hemoccult II SENSA for fecal occult blood testing. Am J Gastroenterol. 1995;90:2160–3.PubMed
17.
go back to reference Faivre J, Dancourt V, Lejeune C. Screening for colorectal cancer with immunochemical faecal occult blood tests. Dig Liver Dis. 2012;44:967–73.CrossRef Faivre J, Dancourt V, Lejeune C. Screening for colorectal cancer with immunochemical faecal occult blood tests. Dig Liver Dis. 2012;44:967–73.CrossRef
18.
go back to reference Huang Y, Li Q, Ge W, Cai S, Zhang S, Zheng S. Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm. Eur J Cancer Prev. 2014;23:27–34.CrossRef Huang Y, Li Q, Ge W, Cai S, Zhang S, Zheng S. Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm. Eur J Cancer Prev. 2014;23:27–34.CrossRef
19.
go back to reference Huddy JR, Ni MZ, Markar SR, Hanna GB. Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions. World J Gastroenterol. 2015;21:4111–20.CrossRef Huddy JR, Ni MZ, Markar SR, Hanna GB. Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions. World J Gastroenterol. 2015;21:4111–20.CrossRef
20.
go back to reference Mimee M, Nadeau P, Hayward AA, Carim S, Flanagan S, Jerger L, et al. An ingestible bacterial-electronic system to monitor gastrointestinal health. Science. 2018;360:915–8.CrossRef Mimee M, Nadeau P, Hayward AA, Carim S, Flanagan S, Jerger L, et al. An ingestible bacterial-electronic system to monitor gastrointestinal health. Science. 2018;360:915–8.CrossRef
21.
go back to reference Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49:3049–54.CrossRef Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49:3049–54.CrossRef
22.
go back to reference Imperiale T. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med. 2007;146:309–11.CrossRef Imperiale T. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med. 2007;146:309–11.CrossRef
23.
go back to reference Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009;150:162–9.CrossRef Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009;150:162–9.CrossRef
24.
go back to reference Cruz-Correa M, Schultz K, Jagannath S, Harris M, Kantsevoy S, Bedine M, et al. Performance characteristics and comparison of two fecal occult blood tests in patients undergoing colonoscopy. Dig Dis Sci. 2007;52:1009–13.CrossRef Cruz-Correa M, Schultz K, Jagannath S, Harris M, Kantsevoy S, Bedine M, et al. Performance characteristics and comparison of two fecal occult blood tests in patients undergoing colonoscopy. Dig Dis Sci. 2007;52:1009–13.CrossRef
26.
go back to reference Rockey DC, Auslander A, Greenberg PD. Detection of upper gastrointestinal blood with fecal occult blood tests. Am J Gastroenterol. 1999;94:344–50.CrossRef Rockey DC, Auslander A, Greenberg PD. Detection of upper gastrointestinal blood with fecal occult blood tests. Am J Gastroenterol. 1999;94:344–50.CrossRef
27.
go back to reference Young GP, St John DJ, Rose IS, Blake D. Haem in the gut. Part II. Faecal excretion of haem and haem-derived porphyrins and their detection. J Gastroenterol Hepatol. 1990;5:194–203.CrossRef Young GP, St John DJ, Rose IS, Blake D. Haem in the gut. Part II. Faecal excretion of haem and haem-derived porphyrins and their detection. J Gastroenterol Hepatol. 1990;5:194–203.CrossRef
28.
go back to reference Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–55.CrossRef Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–55.CrossRef
29.
go back to reference Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–97.CrossRef Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–97.CrossRef
30.
go back to reference Lucas AL, Hwang C, Frucht H. Strengthening the case for stool DNA tests as first-line colorectal cancer screening: are we there yet? Clin Gastroenterol Hepatol. 2012;10:214–5.CrossRef Lucas AL, Hwang C, Frucht H. Strengthening the case for stool DNA tests as first-line colorectal cancer screening: are we there yet? Clin Gastroenterol Hepatol. 2012;10:214–5.CrossRef
31.
go back to reference Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–56.CrossRef Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–56.CrossRef
32.
go back to reference Imperiale T, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med. 2004;351:2704–14.CrossRef Imperiale T, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med. 2004;351:2704–14.CrossRef
33.
go back to reference Frossard JL, Peyer R. Fecal DNA for colorectal cancer screening. N Engl J Med. 2005;352:1384–5.CrossRef Frossard JL, Peyer R. Fecal DNA for colorectal cancer screening. N Engl J Med. 2005;352:1384–5.CrossRef
34.
go back to reference Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.CrossRef Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.CrossRef
35.
go back to reference Malik P. A novel multitarget stool DNA test for colorectal cancer screening. Postgrad Med. 2016;128:268–72.CrossRef Malik P. A novel multitarget stool DNA test for colorectal cancer screening. Postgrad Med. 2016;128:268–72.CrossRef
36.
go back to reference Ren A, Dong Y, Tsoi H, Yu J. Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci. 2015;16:2810–23.CrossRef Ren A, Dong Y, Tsoi H, Yu J. Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci. 2015;16:2810–23.CrossRef
Metadata
Title
Faecal Occult Blood Point-of-Care Tests
Authors
Barbara Kościelniak-Merak
Branimir Radosavljević
Andrzej Zając
Przemysław J. Tomasik
Publication date
01-12-2018
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2018
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0169-1

Other articles of this Issue 4/2018

Journal of Gastrointestinal Cancer 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.